ArticleInternational wound journal2026
Arginine-Enriched Oral Nutritional Supplement as an Adjunct to Standard of Care in the Treatment of Recalcitrant Venous Leg Ulcers.
Article in International wound journal, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
Venous leg ulcers (VLUs) are common, difficult to heal, and prone to recurrence. Malnutrition and impaired nitric-oxide-dependent microcirculation may contribute to recalcitrance. Arginine-enriched oral nutritional supplements (ONS) improve healing in other wound types, but data in VLUs is limited. We conducted a prospective single-arm study evaluating arginine-enriched ONS (L-arginine 4.5 g, vitamins C, E) as an adjunct to evidence-based standard care (compression, debridement, infection control and venotonic/hemorheologic agents). Adults with recalcitrant VLUs received daily ONS for 8 weeks. Primary outcome was change in ulcer area; secondary outcomes included complete healing, adverse events and exploratory correlations. Ten patients with chronic VLUs were enrolled. Median prior duration of conventional therapy before ONS was substantial at 32.5 months. From baseline to week 8, mean ulcer area decreased significantly from 30.5 to 21.4 cm
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.